—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib ...

Subscribers to Chart of the Week received this commentary on Sunday, September 8. One of the most popular and utilized technical indicators for contrarian investors is short interest, one of the three tiers of Sehaeffers' Expectational Analysis®. Short interest and squeezes are so important to what we do that Scnior Quantitiative Analyst Rocky White has compiles a bi-weekly shots squecze screen that helps identify outlier technical setups. Usings strict liquidity data to limit the total number of stocks pul ...

Shares of Insmed (INSM) have more than doubled in market value in the past six months against the industry's 1.1% fall. During this timeframe, the stock has also outperformed the sector and the S&P 500. The surge in stock price can be attributed to the company's progress with its two pipeline candidates, brensocatib and treprostinil palmitil inhalation powder (TPIP), which are being developed in separate clinical studies targeting multiple lung disorders. The company's shares are also trading above the 50-d ...

Insmed Incorporated (NASDAQ:INSM) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Bryan Dunn – Head-Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Jessica Fye – JPMorgan Ritu Baral – TD Cowen Joseph Schwartz – Leerink Partners Cameron Bozdog – Bank of America Jennifer Kim – Cantor Fitzgerald Leon Wang – Barclays Vamil Divan – Guggenheim Securities Li ...

Insmed (INSM) reported a loss of $1.94 per share in second-quarter 2024, wider than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter, the company posted a loss of $1.78. Insmed generated total revenues of $90.3 million during the quarter, up 17% year over year. Quarterly sales beat the Zacks Consensus Estimate of $88.0 million. Quarter in Detail In the reported quarter, total revenues were generated entirely from product revenues of its only-marketed drug, Arikayce, which is approved ...

Insmed (INSM) reported $90.34 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 17%. EPS of -$1.94 for the same period compares to -$1.78 a year ago. The reported revenue represents a surprise of +2.71% over the Zacks Consensus Estimate of $87.96 million. With the consensus EPS estimate being -$1.22, the EPS surprise was -59.02%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

Insmed (INSM) came out with a quarterly loss of $1.94 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.78 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -59.02%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.22 per share when it actually produced a loss of $1.06, delivering ...

Exhibit 99.1 Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— —Primary Endpoint for ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Infection ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 54-1972729 (State or other jurisdiction ...

A replay of the conference call will be accessible approximately 1 hour after its completion through September 7, 2024, by dialing (800) 770-2030 (U.S.) and (609) 800-9909 (international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 8, 2024, to discuss the financial results an ...